Clinical outcomes are complex and often involve multiple systems. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical outcomes, imaging inspections, laboratory tests, and pathological checks.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of HL with COVID. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.